Mechanisms of action of recombinant activated factor VII in the context of tissue factor concentration and distribution

Blood Coagulation and Fibrinolysis

Volumn 19, Issue 8, 2008, Pages 743-755

  Ovanesov, Mikhail V ^a,b,e   Panteleev, Mikhail A ^a   Sinauridze, Elena I ^a   Kireev, Dmitry A ^a   Plyushch, Olga P ^a   Kopylov, Konstantin G ^a   Lopatina, Elena G ^a   Saenko, Evgueni L ^b   Ataullakhanov, Fazoil I ^a,c,d  

^a NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c MOSCOW STATE UNIVERSITY   (Russian Federation)

^d CENTER FOR THEORETICAL PROBLEMS OF PHYSICOCHEMICAL PHARMACOLOGY   (Russian Federation)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Factor VIIa; NovoSeven; Spatial clot propagation; Thrombin generation; Tissue factor

Indexed keywords

FIBRIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; THROMBOPLASTIN;

ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DRUG MECHANISM; FETUS; FIBROBLAST; HEMOPHILIA A; HUMAN; HUMAN CELL; LIPID BLOOD LEVEL; PRIORITY JOURNAL;

BLOOD COAGULATION; BLOOD PLATELETS; CELL-DERIVED MICROPARTICLES; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR VIIA; FIBRIN; HEMOPHILIA A; HUMANS; KINETICS; RECOMBINANT PROTEINS; THROMBIN; THROMBOPLASTIN;

EID: 57149090766     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3283104093     Document Type: Article

References (53)

1. Kjalke M, Ezban M, Monroe DM, Hoffman M, Roberts HR, Hedner U. High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. Br J Haematol 2001; 114:114-120.
2. Hedner U, Kisiel W. Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. J Clin Invest 1983; 71:1836-1841.
3. Hedner U. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa. Thromb Haemost 1999; 82:531-539.
4. Lusher JM, Roberts HR, Davignon G, Joist JH, Smith H, Shapiro A, et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia 1998; 4:790-798.
5. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80:773-778.
6. Hedner U. Recombinant factor VIIa (NovoSeven) as a hemostatic agent. Semin Hematol 2001; 38:43-47.
7. Mann KG, Butenas S. Mechanism of factor VIIa-dependent coagulation in hemophilia blood [response]. Blood 2002; 100:365.
8. Hoffman M, Monroe DM, Roberts HR. Platelet-dependent action of high-dose factor VIIa. Blood 2002; 100:364-365.
9. Monroe DM, Roberts HR. Mechanism of action of high-dose factor VIIa: points of agreement and disagreement. Arterioscler Thromb Vasc Biol 2003; 23:8-9.
10. Rao LV, Rapaport SI. Factor VIIa-catalyzed activation of factor X independent of tissue factor: its possible significance for control of hemophilic bleeding by infused factor VIIa. Blood 1990; 75:1069-1073.
11. 2+, phospholipids and tissue-factor apoprotein to the activation of human blood-coagulation factor X by activated factor VII. Biochem J 1990; 265:327-336.
12. Hedner U, Ljundberg J, Lund-Hansen T. Comparison of the effect of plasma-derived and recombinant human FVIIa in vitro and in a rabbit model. Blood Coagul Fibrinolysis 1990; 1:145-151.
13. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99:542-547.
14. Telgt DS, Macik BG, McCord DM, Monroe DM, Roberts HR. Mechanism by which recombinant factor VIIa shortens the aPTT: activation of factor X in the absence of tissue factor. Thromb Res 1989; 56:603-609.
15. Panteleev MA, Ananyeva NM, Ataullakhanov FI, Saenko EL. Mathematical models of blood coagulation and platelet adhesion: clinical applications. Curr Pharm Des 2007; 13:1457-1467.
16. van't Veer C, Mann KG. The regulation of the factor VII-dependent coagulation pathway: rationale for the effectiveness of recombinant factor VIIa in refractory bleeding disorders. Semin Thromb Hemost 2000; 26:367-372.
17. van't Veer C, Golden NJ, Mann KG. Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa. Blood 2000; 95:1330-1335.
18. Zur M, Radcliffe RD, Oberdick J, Nemerson Y. The dual role of factor VII in blood coagulation. Initiation and inhibition of a proteolytic system by a zymogen. J Biol Chem 1982; 257:5623-5631.
19. Hoffman M, Monroe DM III. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Semin Hematol 2001; 38:6-9.
20. Monroe DM, Hoffman M, Oliver JA, Roberts HR. A possible mechanism of action of activated factor VII independent of tissue factor. Blood Coagul Fibrinolysis 1998; 9 (Suppl 1):S15-S20.
21. Butenas S, Brummel KE, Branda RF, Paradis SG, Mann KG. Mechanism of factor VIIa-dependent coagulation in hemophilia blood. Blood 2002; 99:923-930.
22. Butenas S, Brummel KE, Paradis SG, Mann KG. Influence of factor VIIa and phospholipids on coagulation in 'acquired' hemophilia. Arterioscler Thromb Vasc Biol 2003; 23:123-129.
23. Panteleev MA, Ananyeva NM, Greco NJ, Ataullakhanov FI, Saenko EL. Factor VIIIa regulates substrate delivery to the intrinsic factor X-activating complex. FEBS J 2006; 273:374-387.
24. Morfini M, Lee M, Messori A. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. Thromb Haemost 1991; 66:384-386.
25. Kasper CK, Aledort L, Aronson D, Counts R, Edson JR, van Eys J, et al. Proceedings: a more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34:612.
26. Ovanesov MV, Krasotkina JV, Ul'yanova LI, Abushinova KV, Plyushch OP, Domogatskii SP, et al. Hemophilia A and B are associated with abnormal spatial dynamics of clot growth. Biochim Biophys Acta 2002; 1572:45-57.
27. Sinauridze EI, Kireev DA, Popenko NY, Pichugin AV, Panteleev MA, Krymskaya OV, Ataullakhanov FI. Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost 2007; 97:425-434.
28. Sinauridze EI, Volkova RI, Krasotkina YV, Sarbash VI, Ataullakhanov FI. Dynamics of clot growth induced by thrombin diffusing into nonstirred citrate human plasma. Biochim Biophys Acta 1998; 1425:607-616.
29. Muller AD, van Deijk WA, Devilee PP, Dam-Mieras MC, Hemker HC. The activity state of factor VII in plasma: two pathways for the cold promoted activation of factor VII. Br J Haematol 1986; 62:367-377.
30. Ovanesov MV, Ananyeva NM, Panteleev MA, Ataullakhanov FI, Saenko EL. Initiation and propagation of coagulation from tissue factor-bearing cell monolayers to plasma: initiator cells do not regulate spatial growth rate. J Thromb Haemost 2005; 3:321-331.
31. Hemker HC, Beguin S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost 1995; 74:134-138.
32. Brinkhous KM, Hedner U, Garris JB, Diness V, Read MS. Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease. Proc Natl Acad Sci U S A 1989; 86:1382-1386.
33. Livnat T, Zivelin A, Martinowitz U, Salomon O, Seligsohn U. Prerequisites for recombinant factor VIIa-induced thrombin generation in plasmas deficient in factors VIII, IX or XI. J Thromb Haemost 2006; 4:192-200.
34. Cawthern KM, van't Veer C, Lock JB, DiLorenzo ME, Branda RF, Mann KG. Blood coagulation in hemophilia A and hemophilia C. Blood 1998; 91:4581-4592.
35. Hemker HC, Giesen PL, Ramjee M, Wagenvoord R, Beguin S. The thrombogram: monitoring thrombin generation in platelet-rich plasma. Thromb Haemost 2000; 83:589-591.
36. Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost 2003; 1:1504-1514.
37. Dubovi EJ, Geratz JD, Tidwell RR. Enhancement of respiratory syncytial virus-induced cytopathology by trypsin, thrombin, and plasmin. Infect Immun 1983; 40:351-358.
38. Striggow F, Riek M, Breder J, Henrich-Noack P, Reymann KG, Reiser G. The protease thrombin is an endogenous mediator of hippocampal neuroprotection against ischemia allow concentrations but causes degeneration at high concentrations. Proc Natl Acad Sci U S A 2000; 97:2264-2269.
39. Gaffney PJ, Edgell TA. The International and 'NIH' units for thrombin-how do they compare? Thromb Haemost 1995; 74:900-903.
40. Parhami-Seren B, Butenas S, Krudysz-Amblo J, Mann KG. Immunologic quantitahon of tissue factors. J Thromb Haemost 2006; 4:1747-1755.
41. Balasubramanian V, Grabowski E, Bini A, Nemerson Y. Platelets, circulating tissue factor, and fibrin colocalize in ex vivo thrombi: real-time fluorescence images of thrombus formation and propagation under defined flow conditions. Blood 2002; 100:2787-2792.
42. Ataullakhanov FI, Guria GT, Sarbash VI, Volkova RI. Spatiotemporal dynamics of clotting and pattern formation in human blood. Biochim Biophys Acta 1998; 1425:453-468.
43. Panteleev MA, Ovanesov MV, Kireev DA, Shibeko AM, Sinauridze EI, Ananyeva NM, et al. Spatial propagation and localization of blood coagulation are regulated by intrinsic and protein C pathways, respectively. Biophys J 2006; 90:1489-1500.
44. Taube J, McWilliam N, Luddington R, Byrne CD, Baglin T. Activated protein C resistance: effect of platelet activation, platelet-derived microparticles, and atherogenic lipoproteins. Blood 1999; 93:3792-3797.
45. Zivelin A, Livnat T, Salomon O, Martinowitz U, Seligsohn U. Plasma tissue factor is partially responsible for increased thrombin generation induced by recombinant factor VIIa in factor VIII or factor XI deficient plasmas. Blood 2003; 102:A2934.
46. Lisman T, Mosnier LO, Lambert T, Mauser-Bunschoten EP, Meijers JC, Nieuwenhuis HK, de Groot PG. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood 2002; 99:175-179.
47. Hedner U. Dosing with recombinant factor VIIa based on current evidence. Semin Hematol 2004; 41:35-39.
48. Kenet G, Lubetsky A, Luboshitz J, Martinowitz U. A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven). J Thromb Haemost 2003; 1:450-455.
49. Broze GJ Jr, Higuchi DA. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood 1996; 88:3815-3823.
50. Sixma JJ, van den Berg A. The haemostatic plug in haemophilia A: a morphological study of haemostatic plug formation in bleeding time skin wounds of patients with severe haemophilia A. Br J Haematol 1984; 58:741-753.
51. Ovanesov MV, Sinauridze EI, Panteleev MA, Plyushch OP, Kopylov KG, Lopatina EG, Ataullakhanov FI. Comparative study of the effect of recombinant factor VIIa on clot growth and thrombin generation in normal and hemophilia A plasma in vitro [abstract P1109]. J Thromb Haemost 2003; 1:.
52. Tonda R, Galan AM, Mazzara R, White JG, Ordinas A, Escolar G. Platelet membrane fragments enhance the procoagulant effect of recombinant factor VIIa in studies with circulating human blood under conditions of experimental thrombocytopenia. Semin Hematol 2004; 41:157-162.
53. Proulle V, Hugel B, Guillet B, Trichet C, Rafowicz A, Lambert T, et al. Injection of recombinant activated factor VII can induce transient increase in circulating procoagulant microparticles. Thromb Haemost 2004; 91:873-878.